Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib-Reference-Cited by-同舟云学术

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

Published:2019-02-01 Issue:2 Volume:5 Page:164
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Bex Axel¹,Mulders Peter²,Jewett Michael³,Wagstaff John⁴,van Thienen Johannes V.¹,Blank Christian U.¹,van Velthoven Roland⁵,del Pilar Laguna Maria⁶,Wood Lori⁷,van Melick Harm H. E.⁸,Aarts Maureen J.⁹,Lattouf J. B.¹⁰,Powles Thomas¹¹,de Jong, MD, PhD Igle Jan¹²,Rottey Sylvie¹³,Tombal Bertrand¹⁴,Marreaud Sandrine¹⁵,Collette Sandra¹⁵¹⁶,Collette Laurence¹⁵,Haanen John¹

Affiliation:

1. The Netherlands Cancer Institute, Amsterdam, the Netherlands

2. Department of Urology, Radboud University Hospital, Nijmegen, the Netherlands

3. Department of Urology, Princess Margaret Hospital, Toronto, Ontario, Canada

4. Department of Oncology, Cardiff Hospital, Wales, United Kingdom

5. Department of Urology, Institut Jules Bordet, Brussels, Belgium

6. Department of Urology, Istanbul Medipol University, Istanbul, Turkey

7. Division of Medical Oncology, QEII Health Sciences Center, Halifax, Nova Scotia, Canada

8. Department of Urology, Saint Antonius Hospital, Nieuwegein, the Netherlands

9. Department of Oncology, Maastricht University Medical Center, Maastricht, the Netherlands

10. Department of Surgery-Urology, University of Montreal Hospital Center, Quebec, Ontario, Canada

11. Department of Oncology, The Royal Free Hospital and Queen Mary University, London, United Kingdom

12. Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

13. Department of Medical Oncology, Ghent University Hospital, Ghent, Belgium

14. Department of Urology, Cliniques Universitaires Saint-Luc, Brussels, Belgium

15. Department of Statistics, European Organisation for Research and Treatment of Cancer, Brussels, Belgium

16. Currently with Bristol-Myers Squibb, Brussels, Belgium

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

http:///jamaoncology/article-pdf/5/2/164/17295306/jamaoncology_bex_2018_oi_180100.pdf

Reference30 articles.

1. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.;Flanigan;N Engl J Med,2001

2. Radical nephrectomy plus interferon-alfa–based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.;Mickisch;Lancet,2001

3. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.;Flanigan;J Urol,2004

4. EAU guidelines on renal cell carcinoma: 2014 update.;Ljungberg;Eur Urol,2015

5. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.;Motzer;J Clin Oncol,1999

Cited by 361 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of Cytoreductive Nephrectomy in Metastatic Clear Cell Renal cell Carcinoma in the Era of immunotherapy: An Analysis of the National Cancer Database;Clinical Genitourinary Cancer;2024-12

2. Effect of Treatment of Residual Disease After Immunotherapy-Based Combinations on Complete Response Rate of Patients With Metastatic Renal Cell Carcinomas;Clinical Genitourinary Cancer;2024-10

3. Focal therapy for oligometastatic and oligoprogressive renal cell carcinoma: a narrative review;Future Oncology;2024-09-11

4. Conséquences chirurgicales et anatomopathologiques de l’immunothérapie préopératoire en onco-urologie;Bulletin du Cancer;2024-09

5. Sarcomatoid Renal Clear Cell Carcinoma with Brain Metastasis: A Case Report and Literature Review;British Journal of Hospital Medicine;2024-08-30